FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 288 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR New on NCI’s Website for July 2023 – Researcher/Trainee Special Edition July 21, 2023 New tool to tackle gaps in public’s knowledge of blood cancer... July 14, 2023 High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent... June 8, 2022 Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 Load more HOT NEWS 105-Year-Old Woman Sets Record For 100-Meter Dash Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from... Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of... New Class of Compounds Rewires Cancer Cells to Self-Destruct
